Objective:
To evaluate the effectiveness and safety of the Calibreye Titratable Glaucoma Therapy surgical system in patients with moderate to severe glaucoma.
Key Findings:
- 44.9% reduction in intraocular pressure (IOP) compared to baseline.
- Average postoperative IOP of 12.1 mmHg.
- 88% of patients were medication-free, with an average reduction of more than three medications per patient.
- One case of hypotony maculopathy led to device explantation.
Interpretation:
The Calibreye system demonstrates significant potential for IOP reduction and medication independence, with the ability to adjust flow settings in-office using a laser.
Limitations:
- Small sample size of 33 patients with only three months of follow-up.
- One case of device explantation due to complications.
Conclusion:
The Calibreye Titratable Glaucoma Therapy system shows promise for managing glaucoma, allowing for real-time adjustments to IOP.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.